| Literature DB >> 31682434 |
Phillip R Lazzara, Brian P David, Aparna Ankireddy, Benjamin G Richardson, Katherine Dye, Kiira M Ratia, Sekhar P Reddy, Terry W Moore.
Abstract
Pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) arises from blocking the interaction of NRF2 with its negative regulator, KEAP1 (Kelch-like ECH-associated protein 1). We previously reported an isoquinoline-based NRF2 activator, but this compound showed negative logD7.4 and a -2 charge at physiological pH, which may have limited its membrane permeability. In this work, we report potent, metabolically stable analogs that result from replacing a carboxymethyl group at the 4-position with a fluoroalkyl group.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31682434 PMCID: PMC7315935 DOI: 10.1021/acs.jmedchem.9b01074
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446